Skip to main content

Table 1 Baseline characteristics of patients with hepatocellular carcinoma in this study and in the original SNACOR study [7]

From: Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma

   This study Original SNACOR study
n = 268 % n = 340 %
Prior to first TACE      
Age, y Mean ± SD 66.5 ± 9.4   58  
  Range 36.1–87.3   51–65  
Sex Male 227 84.7 274 80.6
  Female 41 15.3 66 19.4
Aetiologya Alcohol 134 50.0   
  Hepatitis B virus 24 9.0 242 71.2
  Hepatitis C virus 77 28.7 44 12.9
  Otherb 42 15.7 54 15.9
  No underlying liver disease 9 3.3 0 0
Child Pugh stage A 184 68.7 288 84.7
  B 84 31.3 52 15.3
Tumour size, mm Mean ± SD 52 ± 35   53  
  Range 10–215   27–88  
Number of nodes 1 78 29.1 127 37.4
  2 80 29.9 74 21.8
  3 44 16.4 31 9.1
  4 36 13.4 31 9.1
  ≥5 30 11.2 77 22.6
Alpha–fetoprotein, ng/ml Median 30.5   120.0  
  Range 0.5–920,910   17.1–1430.0  
  1. athe sum of aetiologies is > 100% because patients could have two or more aetiologies
  2. b“other” comprises: nonalcoholic steatohepatitis (n = 17; 6.3%), cryptogenic liver cirrhosis (n = 14; 5.2%), hemochromatosis (n = 11; 4.1%)